Document is current
Any future updates will be listed below
-
Authors
,
Lotta, Luca A.
Pietzner, Maik
Stewart, Isobel D.
Wittemans, Laura B. L.
Li, Chen
Bonelli, Roberto
Raffler, Johannes https://orcid.org/0000-0003-2495-4020
Biggs, Emma K.
Oliver-Williams, Clare
Auyeung, Victoria P. W. https://orcid.org/0000-0002-0823-3963
Luan, Jian’an https://orcid.org/0000-0003-3137-6337
Wheeler, Eleanor https://orcid.org/0000-0002-8616-6444
Paige, Ellie https://orcid.org/0000-0003-0855-9872
Surendran, Praveen
Michelotti, Gregory A.
Scott, Robert A. https://orcid.org/0000-0003-3634-3016
Burgess, Stephen https://orcid.org/0000-0001-5365-8760
Zuber, Verena https://orcid.org/0000-0001-9827-1877
Sanderson, Eleanor https://orcid.org/0000-0001-5188-5775
Koulman, Albert https://orcid.org/0000-0001-9998-051X
Imamura, Fumiaki https://orcid.org/0000-0002-6841-8396
Forouhi, Nita G. https://orcid.org/0000-0002-5041-248X
Khaw, Kay-Tee
Griffin, Julian L.
Wood, Angela M.
Kastenmüller, Gabi https://orcid.org/0000-0002-2368-7322
Danesh, John
Butterworth, Adam S. https://orcid.org/0000-0002-6915-9015
Gribble, Fiona M.
Reimann, Frank https://orcid.org/0000-0001-9399-6377
Bahlo, Melanie https://orcid.org/0000-0001-5132-0774
Fauman, Eric https://orcid.org/0000-0002-9739-0249
Wareham, Nicholas J. https://orcid.org/0000-0003-1422-2993
Langenberg, Claudia https://orcid.org/0000-0002-5017-7344
- License Information
-
More Information
Article History
Received: 4 February 2020
Accepted: 20 November 2020
First Online: 7 January 2021
Competing interests
: A.S.B. received grants from AstraZeneca, Biogen, Bioverativ, Merck, Novartis and Sanofi. J.D. sits on the International Cardiovascular and Metabolic Advisory Board for Novartis (since 2010), the Steering Committee of UK Biobank (since 2011), is a member of the MRC International Advisory Group, London (since 2013), the MRC High Throughput Science ’Omics Panel, London (since 2013) and serves on the Scientific Advisory Committee for Sanofi (since 2013), the International Cardiovascular and Metabolism Research and Development Portfolio Committee for Novartis and the AstraZeneca Genomics Advisory Board (since 2018). E.F. is an employee and stock holder of Pfizer. L.A.L. is presently an employee and shareholder of Regeneron Pharmaceuticals Inc. The remaining authors declare no competing interests.
